Shares of ClearOne extended their explosive rally Monday, trading at $7.79 in pre-market — up 20.2% from the prior close and roughly 148% above levels from a week ago — as speculative momentum continued to build around the company's planned reverse merger with Cortigent, a brain-computer interface developer spun out of Vivani Medical.
• An Empty Shell Gets a New Identity — and New Owners. ClearOne's board approved a plan last September to sell off its operating assets and position itself as a reverse-merger vehicle.
The company divested its legacy audio and video conferencing business to Biamp in October 2025. What remained was essentially a publicly listed corporate shell. The new entity, Cortigent Holdings, is expected to close in Q3 2026 and trade under the ticker "CRGT." For shareholders, the practical question is what they are actually buying: a Nasdaq listing with no meaningful operating business until the deal closes.
• Legacy Shareholders Are Getting Heavily Diluted. Vivani will receive 12.5 million shares and own 59.4% to 67.5% of the combined company, leaving former ClearOne holders with just 12.7% to 14.4%.
A planned $10–15 million equity raise at closing will add further dilution. At today's price, the market is valuing the combined entity at roughly $40–50 million before new shares are issued — a steep price for a pre-commercial medical device company with zero revenue from its brain-implant pipeline.
• The Technology Is Ambitious but Pre-Revenue. Cortigent's portfolio includes implantable neurostimulation devices targeting artificial vision for the blind and stroke rehabilitation for paralyzed limbs — both enormous unmet medical needs. These technologies trace back to Second Sight Medical, which merged into what became Vivani in 2022. None of these products generate meaningful revenue today, and regulatory and clinical hurdles remain steep.
• The Rally Has All the Hallmarks of Speculative Momentum. On the announcement day, CLRO's price spiked intraday to $9.62 before closing at $6.48 — a round-trip that signals aggressive buying followed by equally aggressive profit-taking. Investors are "effectively swapping into an early-stage med-tech development play with minority economic interest and heavy dilution." The BCI sector's Neuralink-fueled hype is real, but enthusiasm alone doesn't validate a $7.79 share price for a company that is, for now, little more than a promise stapled to a ticker symbol.